CYP2C19

The TAILOR-PCI Randomized Clinical Trial

Genotype-guided therapy resulted in 34% fewer adverse events after 12 months such as death, stroke, second heart attack, and stent thrombosis.
Genotype-guided therapy resulted in 79% fewer adverse events in the first 3 months. According to principal investigator Dr. Naveen Pereira: “This finding suggests that the lion’s share of the benefit of genetically guided therapy may occur during this high-risk period.”
The TAILOR-PCI trial used Spartan’s RX CYP2C19 System.

Explore Related Resources

Which Test Are You Looking For?